Abstract:Intracerebral hemorrhage (ICH) is a devastating disease with high rates of mortality and morbidity. The major risk factors for ICH include chronic arterial hypertension and oral anticoagulation. After the initial hemorrhage, hematoma expansion and perihematoma edema result in secondary brain damage and worsened outcome. A rapid onset of focal neurological deficit with clinical signs of increased intracranial pressure is strongly suggestive of a diagnosis of ICH, although cranial imaging is required to differentiate it from ischemic stroke. ICH is a medical emergency and initial management should focus on urgent stabilization of cardiorespiratory variables and treatment of intracranial complications. More than 90% of patients present with acute hypertension, and there is some evidence that acute arterial blood pressure reduction is safe and associated with slowed hematoma growth and reduced risk of early neurological deterioration. However, early optimism that outcome might be improved by the early administration of recombinant factor VIIa (rFVIIa) has not been substantiated by a large phase III study. ICH is the most feared complication of warfarin anticoagulation, and the need to arrest intracranial bleeding outweighs all other considerations. Treatment options for warfarin reversal include vitamin K, fresh frozen plasma, prothrombin complex concentrates, and rFVIIa. There is no evidence to guide the specific management of antiplatelet therapy-related ICH. With the exceptions of placement of a ventricular drain in patients with hydrocephalus and evacuation of a large posterior fossa hematoma, the timing and nature of other neurosurgical interventions is also controversial. There is substantial evidence that management of patients with ICH in a specialist neurointensive care unit, where treatment is directed toward monitoring and managing cardiorespiratory variables and intracranial pressure, is associated with improved outcomes. Attention must be given to fluid and glycemic management, minimizing the risk of ventilator-acquired pneumonia, fever control, provision of enteral nutrition, and thromboembolic prophylaxis. There is an increasing awareness that aggressive management in the acute phase can translate into improved outcomes after ICH.

Intracerebral haemorrhage — mechanisms, diagnosis and prospects for treatment and prevention

Intracerebral hemorrhage: an update on diagnosis and treatment

Magnesium: Pathophysiological mechanisms and potential therapeutic roles in intracerebral hemorrhage

Secondary mechanisms of injury and viable pathophysiological targets in intracerebral hemorrhage

Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions

[Acute treatment of intracerebral hemorrhage]

The acute management of intracerebral hemorrhage: a clinical review

Intracerebral Hemorrhage: A Brief Evidence-Based Review of Common Etiologies, Mechanisms of Secondary Injury, and Medical and Surgical Management

Treatment for intracerebral hemorrhage: Dawn of a new era

[Treatment of intracerebral hemorrhage - An overview]

Advances in Prehospital Management of Intracerebral Hemorrhage

Stem Cell Therapy: A Promising Therapeutic Method for Intracerebral Hemorrhage.

Neuroinflammation after Intracerebral Hemorrhage and Potential Therapeutic Targets

Potential therapeutic targets for intracerebral hemorrhage-associated inflammation: An update

Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage

Emerging therapeutic targets associated with the immune system in patients with intracerebral haemorrhage (ICH): From mechanisms to translation

Ultra-Early Hemostatic Therapy for Acute Intracerebral Hemorrhage: An Updated Review

An Update on Inflammation in the Acute Phase of Intracerebral Hemorrhage

Mechanism and application of immune interventions in intracerebral haemorrhage

Essential Topics About the Imaging Diagnosis and Treatment of Hemorrhagic Stroke: A Comprehensive Review of the 2022 AHA Guidelines

Mechanisms and potential therapeutic targets for spontaneous intracerebral hemorrhage